[Predictive and Prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy].
Objective:To study the predictive and prognostic significance of high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) on the effect of neoadjuvant chemotherapy for advanced gastric cancer.Methods:117 patients with advanced gastric cancer received neoadjuvant chemotherapy with SOX (oxaliplatin+ S1) or mFOLFOX 6(oxaliplatin+ CF+ 5-FU) regimen. HS-mGPS was calculated according to blood C-reactive protein (CRP) concentration and serum albumin (ALB) level. The correlation between HS-mGPS and clinicopathological characteristics was determined and the predictors of survival were analyzed.Results:117 patients with stage ⅡB (43 cases), stage Ⅲ (60), and stage Ⅳ (14) received preoperative neoadjuvant chemotherapy. The overall response rate of neoadjuvant chemotherapy was 61.5%(72/117), and the tumor control rate was 88.0% (103/117), with a pathological response rate of 91.5% (107/117). The R0 resection rate was 81.2% (95/117). The median disease-free survival (DFS) was 21.0 (95%CI6.4-35.6) months. The median overall survival (OS) was 39.0 (95%CI21.4-56.6) months. Higher HS-mGPS was associated with higher T stage, local lymph-node metastasis, distant metastasis, lower chemotherapy overall response rate and lower pathological response rate (allP<0.05). The univariate analysis and multivariate analysis showed that higher HS-mGPS, presence of local lymph-node metastasis and non R0 resection were associated with poorer DFS and OS (P<0.05).Conclusion:HS-mGPS can be used to predict the benefits of neoadjuvant chemotherapy and as an independent prognostic factor for survival in patients with advanced gastric cancer.
Department of Oncology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou, Henan 450003, China.
Y
Y
Cui
Department of General Surgery, Henan Cancer Hospital, Zhengzhou University, Zhengzhou, Henan 450008, China.
J
J
Li
Department of General Surgery, Henan Cancer Hospital, Zhengzhou University, Zhengzhou, Henan 450008, China.
Y H
YH
Cao
Department of Oncology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou, Henan 450003, China.
M Y
MY
Liu
Department of Oncology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou, Henan 450003, China.
Z X
ZX
Shi
Department of Oncology, Henan Provincial People's Hospital (Zhengzhou University People's Hospital), Zhengzhou, Henan 450003, China.
T H
TH
Gao
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology
D009944:Organoplatinum Compounds; D012709:Serum Albumin; D002097:C-Reactive Protein; D002955:Leucovorin; D005472:Fluorouracil
Gastric neoplasms; High-sensitivity modified Glasgow Prognostic Score (HS-mGPS); Neoadjuvant chemotherapy; Prognosis; Treatment outcome